How did the performance of Kodak's core imaging versus its pharmaceutical and chemical segments compare?

Based on the information you provided – which consists only of the headline, a brief by‑line, the news symbol, category, source, and the timestamp of the release – there are no specific performance figures or qualitative commentary about Kodak’s different business units.

The news excerpt does not include any details on:

• Revenue, earnings, or margin trends for the core imaging segment (e.g., film, printing, or digital imaging products).
  
• Revenue, earnings, or margin trends for the pharmaceutical and chemical segment (e.g., specialty chemicals, pharmaceutical ingredients, or related services).
  

Because the conference‑call summary you shared does not contain the segment‑level results, I cannot directly compare how Kodak’s core imaging business performed relative to its pharmaceutical and chemical businesses for Q2 2025.

What you can do next

1. Locate the full earnings release or transcript – The complete press release or the earnings‑call transcript typically breaks out results by segment, often showing:

   • Sales growth (or decline) percentages for each segment.
     
   • Operating income or adjusted EBITDA for the imaging vs. pharma/chemical businesses.
     
   • Management commentary on the drivers behind each segment’s performance (e.g., demand trends, pricing, capacity utilization).

2. Check the SEC filing (Form 10‑Q) – Public companies are required to disclose segment financials in their quarterly reports. The 10‑Q for the quarter ending June 30 2025 will have a “Segment Information” table that lets you directly compare the two businesses.

3. Review analyst coverage – Financial analysts often summarize the segment performance in their research notes or earnings preview articles, which can provide a concise comparison.

If you can supply the specific figures or excerpts from the earnings release (e.g., “Imaging revenue fell 12% to $X million, while pharmaceutical and chemical revenue rose 8% to $Y million”), I would be able to craft a detailed, side‑by‑side performance analysis. Until then, the answer must remain that the current news snippet does not contain the needed data to evaluate the relative performance of Kodak’s core imaging versus its pharmaceutical and chemical segments.